Advantage Alpha Capital Partners LP Sells 18,209 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Advantage Alpha Capital Partners LP reduced its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,182 shares of the biotechnology company's stock after selling 18,209 shares during the period. Advantage Alpha Capital Partners LP's holdings in ADMA Biologics were worth $1,186,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock worth $865,000 after purchasing an additional 645 shares during the period. Oregon Public Employees Retirement Fund boosted its position in shares of ADMA Biologics by 1.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after acquiring an additional 700 shares during the period. Mutual of America Capital Management LLC grew its stake in ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock valued at $614,000 after acquiring an additional 751 shares in the last quarter. Maryland State Retirement & Pension System increased its holdings in ADMA Biologics by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock worth $1,365,000 after acquiring an additional 897 shares during the period. Finally, GAMMA Investing LLC lifted its stake in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.10 during trading on Tuesday, hitting $20.22. The company had a trading volume of 2,401,540 shares, compared to its average volume of 3,368,313. ADMA Biologics, Inc. has a 52 week low of $5.90 and a 52 week high of $23.64. The stock has a market capitalization of $4.78 billion, a price-to-earnings ratio of 72.21 and a beta of 0.60. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock's 50-day moving average is $16.84 and its two-hundred day moving average is $18.07.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.